| HOME | HELP | FEEDBACK | HOW TO CITE ABSTRACTS | ARCHIVE | CME INFORMATION | SEARCH |
| ||||||||||||||||||||||||||||||||||||||||
Behavioral and Social Science: Bioethics |
Cancer Institute Research Center, Tehran University of Medical Sciences, Tehran, Iran
Abstract
A26
Introduction: Scientists have long been on a quest to find therapeutic methods to improve the quality of life of cancer patients. Although anticancer drugs have proven effective in slowing the spread of cancer cells throughout the body, their use is considerably limited by their high toxicity. HESA-A is a compound of herbal and marine origin, which contains elements such as strontium, titanium, manganese, nickel, mercury, copper, zinc, cadmium and cesium, as well as organic substances with antitumor and antioxidant properties. All of these constituents have proven antioxidant properties. The effect of HESA-A on the quality of life of patients with end-stage metastatic liver cancer and hepatocellular carcinoma was assessed in this study. Materials and Methods: Thirty patients with metastatic liver cancer and hepatocellular carcinoma for whom no therapeutic plans had been available within the preceding two months were included in this uncontrolled clinical trial. The patients were given 500 mg HESA-A tablets at a dose of 50 mg/kg, daily for two weeks. The changes in the patients' body weight, body temperature, appetite, abdominal pain and other pain experiences, as well as their Karnofsky performance scores were evaluated at weeks 0, 1, 4, 8, and 12 of the study. All body organs were monitored for likely drug side-effects. The results were analyzed with SPSS9 software using repeated measure ANOVA and Student t-test. Results: Prescription of 50 mg/kg HESA-A in 3 separate doses led to significant increase in appetite and a decrease in abdominal pain, as well as other related pain experiences. The maximum therapeutic effect was observed in week 4 of treatment and continued until week 12 (Tables 1, 4, 5). During the course of treatment, the patients' Karnofsky performance scores increased and the patients reported an improvement in their quality of life (Table 6). The improvement of the patients' performance began in week 1 of treatment and was notably significant. The patients' body temperatures did not rise during treatment with HESA-A. A significant decrease in body temperature was observed in weeks 4 and 12 of treatment. HESA-A intake was not associated with any statistically significant increase or decrease in the patients' body weight. A significant decrease in the patients' SGPT levels was observed during the 2nd and 3rd months of treatment. Discussion: Intake of HESA-A was associated with significant increase in the patients' appetite, improvement of their Karnofsky performance scale, and reduction of abdominal pain and other pain experiences between weeks 1 and 12 of treatment, leading to a notable improvement of the patients' quality of life. These changes may be attributed to the effects of organic compounds and rare elements in HESA-A, which have strong anticancer properties and exhibit very low toxicity on normal cells. Keywords Metastatic liver cancer, hepatocellular carcinoma, HESA.A Drug
| HOME | HELP | FEEDBACK | HOW TO CITE ABSTRACTS | ARCHIVE | CME INFORMATION | SEARCH |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
